What a FAERS database study reports about oral side effects of GLP-1 medications

A study published in JDR Clinical and Translational Research looked at how often oral health problems show up in safety reports for GLP-1 receptor agonists. These are the medications used for type 2 diabetes, weight management, and several other conditions. The authors wanted to know whether dental and mouth-related complaints are appearing alongside these drugs as their use grows.

This was not a clinical trial and it was not an animal or cell study. It used postmarketing surveillance data, meaning reports that patients and clinicians voluntarily submit after a drug is on the market. That design matters for how you read the results, and we return to it below.

What the researchers actually did

The team searched the FDA Adverse Event Reporting System, known as FAERS, for five GLP-1 medications: exenatide, liraglutide, semaglutide, dulaglutide, and tirzepatide. They reviewed reports from each drug's market introduction through December 2025.

Across all five drugs they found 364,274 total adverse event reports. Of those, 31,195, or about 8.6%, mentioned something involving the mouth, face, or teeth. They then ran a disproportionality analysis, a statistical method that checks whether a particular symptom is reported more often than you would expect for a given drug.

What they reported

Tirzepatide had the highest overall volume of adverse event reports, which the authors note despite it being one of the more recently approved drugs in the group. Semaglutide showed the largest share of reports that were oral health related.

A few specific signals stood out. Dry mouth produced a significant drug-specific signal for semaglutide. Vomiting, regurgitation, and reflux-related events showed a significant signal across all five drugs. Taste disturbances, including a symptom called dysgeusia, also reached statistical significance for several of the medications. The authors further reported links between vomiting and taste disturbance, and between dry mouth and dysgeusia, most notably with semaglutide and dulaglutide.

What this does and does not establish

This analysis establishes that oral and dental complaints are appearing in the safety reports for these drugs, and that some symptoms are reported more often than chance would predict. That is useful for raising clinical awareness.

It does not establish that the medications cause these symptoms. A reporting signal shows an association in a voluntary database, not proven cause and effect. The study also does not tell you your personal risk, how likely any symptom is, or how long it might last. The authors are explicit that prospective studies are still needed to measure incidence, timing, and the biological mechanisms behind these effects.

One honest limitation

FAERS data is self-selected. Reports are submitted voluntarily, they are not verified the way trial data is, and the total number of reports partly reflects how widely a drug is prescribed and how much attention it gets. A drug with more users or more media coverage can generate more reports without being more dangerous. So the raw volume figures should be read with that caveat in mind.

Why this is worth knowing

The practical takeaway from the authors is about communication, not alarm. Knowing that dry mouth, taste changes, and reflux irritation can occur lets clinicians and dental providers watch for early symptoms and offer supportive steps like hydration guidance and closer oral health monitoring. That is the kind of detail worth discussing with the physician managing your care.

At Live Vital, medications including semaglutide and tirzepatide are physician-prescribed and reviewed by Dr. Patrick Taylor, MD. They are not retail products, and a prescription is never guaranteed. Care begins with a medical intake and physician approval at get started, and you can ask about side effects, including the oral symptoms described here, during a free consult at consult. Outcomes and side effects vary by individual.